Koyfin Home > Directory > Health Care > Revance Therapeutics > Net Income Margin

Revance Therapeutics Net Income Margin Chart (RVNC)

Revance Therapeutics annual/quarterly Net Income Margin from 2012 to 2020. Net profit margin, or net margin, is equal to net income or profits divided by total revenue and represents how much profit each dollar of sales generates. Net profit margin is the ratio of net profits or net income to revenues for a company.
  • Revance Therapeutics Net Income Margin for the quarter ending June 06, 2020 was $-20,264m a -344.23% increase of 69,755m year over year
  • Revance Therapeutics Net Income Margin for the last 12 months ending June 06, 2020 was $-42,532m a 55.15% decrease of -23,455m year over year
  • Revance Therapeutics Annual Net Income Margin for 2019 was $-38,603m a 90.10% decrease of -34,779m from 2018
  • Revance Therapeutics Annual Net Income Margin for 2018 was $-3,823m a -1,103.84% increase of 42,202m from 2017
  • Revance Therapeutics Annual Net Income Margin for 2017 was $-46,026m a 35.35% decrease of -16,269m from 2016
Other Margins & Efficiency Metrics:
  • Revance Therapeutics Return on Capital % for the quarter ending September 09, 2018 was -42.91 a 7.87% decrease of -3.38 year over year
  • Revance Therapeutics Return on Equity % for the quarter ending September 09, 2018 was -67.02 a -4.32% increase of 2.89 year over year
View Chart On Koyfin

Quarterly RVNC Net Income Margin Data

06/2020$-20,264m
03/2020$-106,781m
12/2019$-50,928m
09/2019$-90,020m
03/2019$-12,699m
12/2018$-8,340m
09/2018$-1,390m
06/2018$-4,968m
03/2018$-18,154m
12/2017$-97,046m

Annual RVNC Net Income Margin Data

2019$-38,603m
2018$-3,823m
2017$-46,026m
2016$-29,757m
2015$-24,492m
2014$-16,427m
2013$-8,500m
2012$-8,125m
2011$-8,054m